WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H328509
CAS#: 57149-07-2
Description: Naftopidil, also known as Flivas and BM-15275, is an alpha-1-D adrenoceptor antagonist used to treat dysuria in men with benign prostatic hypertrophy.
Hodoodo Cat#: H328509
Name: Naftopidil
CAS#: 57149-07-2
Chemical Formula: C24H28N2O3
Exact Mass: 392.21
Molecular Weight: 392.499
Elemental Analysis: C, 73.44; H, 7.19; N, 7.14; O, 12.23
Synonym: Naftopidil; BM-15275; KT-611; BM 15275; KT 611; BM15275; KT611; Flivas
IUPAC/Chemical Name: 1-(4-(2-methoxyphenyl)piperazin-1-yl)-3-(naphthalen-1-yloxy)propan-2-ol
InChi Key: HRRBJVNMSRJFHQ-UHFFFAOYSA-N
InChi Code: InChI=1S/C24H28N2O3/c1-28-24-11-5-4-10-22(24)26-15-13-25(14-16-26)17-20(27)18-29-23-12-6-8-19-7-2-3-9-21(19)23/h2-12,20,27H,13-18H2,1H3
SMILES Code: OC(COC1=C2C=CC=CC2=CC=C1)CN3CCN(C4=CC=CC=C4OC)CC3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 392.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Yamamoto M, Shimizu T, Shimizu S, Higashi Y, Nakamura K, Fujieda M, Saito M. Effect of naftopidil on brain noradrenaline-induced decrease in arginine-vasopressin secretion in rats. J Pharmacol Sci. 2016 Sep 8. pii: S1347-8613(16)30117-7. doi: 10.1016/j.jphs.2016.09.002. [Epub ahead of print] PubMed PMID: 27666018.
2: Nakagawa YU, Nagaya H, Miyata T, Wada Y, Oyama T, Gotoh A. Piperazine-based Alpha-1 AR Blocker, Naftopidil, Selectively Suppresses Malignant Human Bladder Cells via Induction of Apoptosis. Anticancer Res. 2016 Apr;36(4):1563-70. PubMed PMID: 27069132.
3: Kohjimoto Y, Hagino K, Ogawa T, Inagaki T, Kitamura S, Nishihata M, Iba A, Matsumura N, Hara I. Naftopidil versus flopropione as medical expulsive therapy for distal ureteral stones: results of a randomized, multicenter, double-blind, controlled trial. World J Urol. 2015 Dec;33(12):2125-9. doi: 10.1007/s00345-015-1556-x. Epub 2015 Apr 14. PubMed PMID: 25869815.
4: Sugaya K, Nishijima S, Kadekawa K, Ashitomi K, Ueda T, Yamamoto H, Hattori T. Action of naftopidil on spinal serotonergic neurotransmission for inhibition of the micturition reflex in rats. Neurourol Urodyn. 2016 Apr 29. doi: 10.1002/nau.23028. [Epub ahead of print] PubMed PMID: 27128660.
5: Matsukawa Y, Funahashi Y, Takai S, Majima T, Ogawa T, Narita H, Kato M, Gotoh M. Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: A randomized, prospective study (SNIPER study). J Urol. 2016 Sep 8. pii: S0022-5347(16)31211-3. doi: 10.1016/j.juro.2016.08.111. [Epub ahead of print] PubMed PMID: 27615436.
6: Sugaya K, Nishijima S, Kadekawa K, Ashitomi K, Ueda T, Yamamoto H. Naftopidil improves locomotor activity and urinary frequency in rats with pelvic venous congestion. Biomed Res. 2016;37(4):221-6. doi: 10.2220/biomedres.37.221. PubMed PMID: 27544997.
7: Kadekawa K, Sugaya K, Mukoyama H, Sakumoto M, Shimabukuro H, Shimabukuro S, Matayoshi Y, Onaga T, Ashitomi K, Nishijima S. Influence of Naftopidil on Plasma Monoamine Levels and Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. Low Urin Tract Symptoms. 2016 May;8(2):100-5. doi: 10.1111/luts.12079. Epub 2014 Nov 6. PubMed PMID: 27111621.
8: Peng J, Xiao D, He H, Zhao H, Wang C, Shi T, Shi K. Molecularly imprinted polymeric stir bar: Preparation and application for the determination of naftopidil in plasma and urine samples. J Sep Sci. 2016 Jan;39(2):383-90. doi: 10.1002/jssc.201500751. PubMed PMID: 26541792.
9: Masumori N, Tsukamoto T, Shibuya A, Miyao N, Kunishima Y, Iwasawa A. Three-year outcome analysis of alpha 1-blocker naftopidil for patients with benign prostatic hyperplasia in a prospective multicenter study in Japan. Patient Prefer Adherence. 2016 Jul 22;10:1309-16. doi: 10.2147/PPA.S110440. eCollection 2016. PubMed PMID: 27524886; PubMed Central PMCID: PMC4966686.
10: Tanuma Y, Tanaka Y, Takeyama K, Okamoto T. Does prostate volume affect the efficacy of α1D/A: Adrenoceptor antagonist naftopidil? Urol Ann. 2016 Jan-Mar;8(1):20-5. doi: 10.4103/0974-7796.157979. PubMed PMID: 26834396; PubMed Central PMCID: PMC4719506.
